Phase 1 trial of azer-cel reports good preliminary safety and efficacy
Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Findings may have implications for understanding the disorders’ pathophysiology
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Nearly one-fifth of such cases fulfill 2024 McDonald criteria based on biomarkers
Updates on this fast-evolving therapeutic landscape from a leading trialist
Two research projects aim to enable more personalized MS care in this population
How to use? Consider starting during the acute attack and seek patient preferences for chronic use
Despite safety concerns and mixed trial results, experts see potential for this indication
Study looked at mobility measures and safety
Advertisement
Advertisement